The rise of antibiotic resistance has intensified the search for novel antimicrobial compounds, and bioprospecting of natural products from underexplored environments remains an effective strategy. The genus Streptomyces is one of the most prolific sources of pharmacologically active secondary metabolites, whose biosynthetic information is encoded in biosynthetic gene clusters (BGCs). However, many BGCs remain transcriptionally silent under standard laboratory conditions, underscoring the need to characterize the regulatory mechanisms governing their activation. In this study, we sequenced and analyzed the genome of Streptomyces sp. NCA360. The strain was isolated from sediments of the coastal cenote (a natural sinkhole) in the Yucatán Peninsula and selected for its antimicrobial and enzymatic activities. The high- quality genome assembly (89.7% completeness, <1% contamination) encoded 26 BGCs, of which 11 showed low similarity to characterized clusters and were classified as putatively novel (nBGCs). Resistance-guided prioritization identified duplicated resistance determinants, including an additional glyceraldehyde-3-phosphate dehydrogenase copy within a PKS-II cluster and Biotin_lipoyl/Carboxyl_trans domains within two divergent NRPS/PKS-I clusters, that were classified as candidate chemotherapeutic gene clusters. Biosynthetic pathways associated with clinically relevant antibiotics, including monobactams, carbapenems, and cephalosporins, were also detected. The regulatory architecture of the nBGCs revealed 26 regulatory genes, 20 transcription factor binding sites, and 20 rare TTA codons, reflecting heterogeneous and often multifactorial regulatory schemes. In silico protein-protein interaction analysis further revealed a coordinated cross-cluster regulation. The analysis of Streptomyces sp. NCA360 genome expands our understanding of the biosynthetic and regulatory diversity of Streptomyces and highlights the potential of cenotes as unique environments and reservoirs of new bioactive compounds with pharmaceutical relevance.
Rare actinobacteria are promising sources of specialized metabolites, yet genome mining still prioritizes genomes encoding many biosynthetic gene clusters (BGCs) rather than clusters that are distant from characterized chemistry. Here, we describe the isolation of a novel Jiangella strain reported from a marine, animal...
Ruggero Baviera, F. Capri, Paola Galluzzo et al.· Marine Drugs· 0 citations
The genus Amycolatopsis, belonging to the phylum Actinobacteria, is known for producing diverse bioactive secondary metabolites and plays a significant role in microbial drug discovery. This study centers on the strain TRM77291, sourced from a unique habitat, and is postulated to represent a potential new species. This...
Yi-Huang Chen, Lu-Yao Wang, Tao Luo et al.· Microorganisms· 0 citations
The effectiveness of integrated genome-mining strategies for prioritizing cryptic biosynthetic gene clusters is demonstrated and the remarkable biosynthetic potential of newly identified Streptomyces isolates as a source of novel natural products is highlighted.
Nada S. Al-Theyab, Haila M. Alnassar, Mohanad A. Ibrahim et al.· Frontiers in Microbiology· 0 citations
This study provides the first comprehensive genomic characterisation of a pyoluteorin-BGC-harbouring marine P. aeruginosa strain, demonstrating conservation of the core biosynthetic machinery alongside an expanded transport architecture and a divergent FDH-like sequence that may represent a candidate for future biochem...
S. Akinde, E. Fajoyegbe, O. Olaniyan et al.· Antonie van Leeuwenhoek· 0 citations